As GLP-1 and GLP-2 have become important targets in the treatment of type 2 diabetes, obesity and malabsorptive conditions16,17,62, we therefore characterized gut microbiome signatures in DIO mice treated with liraglutide, a selective GLP-1 receptor agonist, or GUB09-145, a potent dual GLP-1/GLP-2 agonist26. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.